vs
Pacira BioSciences, Inc.（PCRX）与Bristow Group Inc.（VTOL）财务数据对比。点击上方公司名可切换其他公司
Bristow Group Inc.的季度营收约是Pacira BioSciences, Inc.的2.1倍（$377.3M vs $177.4M），Bristow Group Inc.净利率更高（4.9% vs 1.6%，领先3.2%），Bristow Group Inc.同比增速更快（6.7% vs 5.0%），过去两年Bristow Group Inc.的营收复合增速更高（5.8% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
布里斯托集团旗下的布里斯托直升机有限公司是英国民用直升机运营企业，最初扎根于苏格兰阿伯丁机场，目前集团总部设在美国得克萨斯州休斯顿。2020年，布里斯托集团与美国大型商用直升机运营企业Era直升机完成合并，合并后企业沿用布里斯托品牌名称运营。
PCRX vs VTOL — 直观对比
营收规模更大
VTOL
是对方的2.1倍
$177.4M
营收增速更快
VTOL
高出1.7%
5.0%
净利率更高
VTOL
高出3.2%
1.6%
两年增速更快
VTOL
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $377.3M |
| 净利润 | $2.9M | $18.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 8.5% |
| 净利率 | 1.6% | 4.9% |
| 营收同比 | 5.0% | 6.7% |
| 净利润同比 | — | -42.1% |
| 每股收益（稀释后） | $0.07 | $0.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXVTOL
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $377.3M | ||
| Q3 25 | $179.5M | $386.3M | ||
| Q2 25 | $181.1M | $376.4M | ||
| Q1 25 | $168.9M | $350.5M | ||
| Q4 24 | $187.3M | $353.5M | ||
| Q3 24 | $168.6M | $365.1M | ||
| Q2 24 | $178.0M | $359.7M |
净利润PCRXVTOL
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $18.4M | ||
| Q3 25 | $5.4M | $51.5M | ||
| Q2 25 | $-4.8M | $31.7M | ||
| Q1 25 | $4.8M | $27.4M | ||
| Q4 24 | — | $31.8M | ||
| Q3 24 | $-143.5M | $28.2M | ||
| Q2 24 | $18.9M | $28.2M |
毛利率PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXVTOL
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 8.5% | ||
| Q3 25 | 3.5% | 13.1% | ||
| Q2 25 | 4.7% | 11.3% | ||
| Q1 25 | 1.2% | 9.6% | ||
| Q4 24 | 13.2% | 9.0% | ||
| Q3 24 | -82.8% | 9.1% | ||
| Q2 24 | 15.9% | 12.4% |
净利率PCRXVTOL
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 13.3% | ||
| Q2 25 | -2.7% | 8.4% | ||
| Q1 25 | 2.8% | 7.8% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | -85.1% | 7.7% | ||
| Q2 24 | 10.6% | 7.8% |
每股收益（稀释后）PCRXVTOL
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.61 | ||
| Q3 25 | $0.12 | $1.72 | ||
| Q2 25 | $-0.11 | $1.07 | ||
| Q1 25 | $0.10 | $0.92 | ||
| Q4 24 | $0.38 | $1.07 | ||
| Q3 24 | $-3.11 | $0.95 | ||
| Q2 24 | $0.39 | $0.96 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $286.2M |
| 总债务越低越好 | — | $671.5M |
| 股东权益账面价值 | $653.9M | $1.1B |
| 总资产 | $1.2B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.63× |
8季度趋势，按日历期对齐
现金及短期投资PCRXVTOL
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $286.2M | ||
| Q3 25 | $246.3M | $245.5M | ||
| Q2 25 | $445.9M | $251.8M | ||
| Q1 25 | $493.6M | $191.1M | ||
| Q4 24 | $484.6M | $247.5M | ||
| Q3 24 | $453.8M | $200.3M | ||
| Q2 24 | $404.2M | $178.6M |
总债务PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $671.5M | ||
| Q3 25 | $376.7M | $675.0M | ||
| Q2 25 | $580.5M | $705.2M | ||
| Q1 25 | $583.4M | $701.9M | ||
| Q4 24 | $585.3M | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M |
股东权益PCRXVTOL
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $1.1B | ||
| Q3 25 | $727.2M | $1.0B | ||
| Q2 25 | $757.8M | $984.4M | ||
| Q1 25 | $798.5M | $931.7M | ||
| Q4 24 | $778.3M | $891.7M | ||
| Q3 24 | $749.6M | $899.2M | ||
| Q2 24 | $879.3M | $849.1M |
总资产PCRXVTOL
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.6B | $2.0B |
负债/权益比PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.63× | ||
| Q3 25 | 0.52× | 0.65× | ||
| Q2 25 | 0.77× | 0.72× | ||
| Q1 25 | 0.73× | 0.75× | ||
| Q4 24 | 0.75× | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $76.9M |
| 自由现金流经营现金流 - 资本支出 | — | $47.8M |
| 自由现金流率自由现金流/营收 | — | 12.7% |
| 资本支出强度资本支出/营收 | — | 7.7% |
| 现金转化率经营现金流/净利润 | — | 4.17× |
| 过去12个月自由现金流最近4个季度 | — | $56.4M |
8季度趋势，按日历期对齐
经营现金流PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $76.9M | ||
| Q3 25 | $60.8M | $23.1M | ||
| Q2 25 | $12.0M | $99.0M | ||
| Q1 25 | $35.5M | $-603.0K | ||
| Q4 24 | $33.1M | $51.1M | ||
| Q3 24 | $53.9M | $66.0M | ||
| Q2 24 | $53.2M | $33.7M |
自由现金流PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $47.8M | ||
| Q3 25 | $57.0M | $-6.2M | ||
| Q2 25 | $9.3M | $67.4M | ||
| Q1 25 | $26.9M | $-52.7M | ||
| Q4 24 | $31.0M | $-32.4M | ||
| Q3 24 | $49.8M | $9.0M | ||
| Q2 24 | $51.6M | $-16.7M |
自由现金流率PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 12.7% | ||
| Q3 25 | 31.7% | -1.6% | ||
| Q2 25 | 5.1% | 17.9% | ||
| Q1 25 | 15.9% | -15.0% | ||
| Q4 24 | 16.6% | -9.2% | ||
| Q3 24 | 29.6% | 2.5% | ||
| Q2 24 | 29.0% | -4.6% |
资本支出强度PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 7.7% | ||
| Q3 25 | 2.2% | 7.6% | ||
| Q2 25 | 1.5% | 8.4% | ||
| Q1 25 | 5.1% | 14.9% | ||
| Q4 24 | 1.1% | 23.6% | ||
| Q3 24 | 2.4% | 15.6% | ||
| Q2 24 | 0.9% | 14.0% |
现金转化率PCRXVTOL
| Q1 26 | — | — | ||
| Q4 25 | — | 4.17× | ||
| Q3 25 | 11.20× | 0.45× | ||
| Q2 25 | — | 3.12× | ||
| Q1 25 | 7.37× | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | 2.82× | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
